advertisement
Abstract #11378 Published in IGR 6-3
Effect of topical brinzolamide 1% and brimonidine 0.2% on intraocular pressure after phacoemulsification
Cetinkaya A; Akman A; Akova YAJournal of Cataract and Refractive Surgery 2004; 30: 1736-1741
PURPOSE: To compare the effectiveness of brinzolamide 1% (Azopt) and brimonidine 0.2% (Alphagan) with a placebo in preventing an early increase in intraocular pressure (IOP) after phacoemulsification. SETTING: Department of Ophthalmology, Baskent University, School of Medicine, Ankara, Turkey. METHODS: In this prospective double-masked study, 90 eyes of 90 patients having clear corneal phacoemulsification were randomly divided into 3 groups of 30 eyes each. One hour before surgery, 1 group received 1 drop of brinzolamide 1%, another received 1 drop of brimonidine 0.2%, and the third received 1 drop of a balanced saline solution (placebo). The IOP was measured preoperatively and 3 and 16 to 20 hours postoperatively. RESULTS: Three hours postoperatively, the mean IOP increased by 4.2 mmHg ± 7.0 (SD), 3.2 ± 6.4 mmHg, and 5.3 ± 4.2 mmHg in the brinzolamide, brimonidine, and placebo groups, respectively. The IOP increase from baseline was significant in all 3 groups (all P < .01), with no difference between the groups (P > .05). The change in IOP at 16 to 20 hours was 0.2 ± 2.8 mmHg, 0.2 ± 2.4 mmHg, and -0.8 ± 2.4 mmHg, respectively. The changes were not significant compared to baseline (all P > .05). Six eyes (20%) in the brinzolamide group, 5 eyes (16.7%) in the brimonidine group, and 7 eyes (23.3%) in the placebo group had an IOP higher than 25 mmHg 3 hours postoperatively; the difference between groups was not significant (P = .8). CONCLUSION: Prophylactic use of 1 drop of brinzolamide or brimonidine was not more effective than a placebo in controlling early postoperative IOP elevations after clear corneal phacoemulsification.
Dr. A. Cetinkaya, Baskent University, School of Medicine, Department of Ophthalmology, Bahcelievler 06490, Ankara, Turkey
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)